Search for a trial

Long-term follow-up and cross-over of treatment with high-density micropulse laser and half-dose photodynamic therapy in participants of the PLACE trial for chronic central serous chorioretinopathy.

Primary objectives:- To investigate the long-term outcome after successful treatment (no subretinal fluid on OCT) in the PLACE trial.- To investigate whether a cross-over treatment of half-dose PDT to HSML in cCSC patients who either did not respond…

Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

The objective of this study is to observe the anatomical and functional outcomes of ocriplasmin over a 6-month follow-up period.

A phase IIIB, one year, open label, multicentre, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium injection in subjects with diabetic macular edema (DME)

The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.

Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.

To examine features of treatment response on optical coherence tomography in patients who were switched to aflibercept after non-response to previous intravitreal anti-VEGF treatment.

A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the
efficacy and safety of an individualized, stabilization criteria-driven pro re rata (PRN) dosing regimen
with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual
impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

The primary objective is to evaluate the efficacy of an individualized stabilization criteriadrivenPRN dosing regimen with 0.5 mg ranibizumab as assessed by the mean best-corrected visualacuity (BCVA) change at Month 12 compared to Baseline.

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular
edema in patients who have completed the RESTORE trial

Primary objective* To evaluate ocular and non-ocular adverse events during the 24-months study period in patients treated with Lucentis (0.5 mg)Secondary objectives* To describe the ocular and non-ocular adverse events over a cumulative 36-months…

A Phase IIIb, open-label, multi-centre, 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

The primary objective of this study is to estimate the incidence of ocular adverse events in patients with CNV secondary to AMD who receive an individualized treatment with ranibizumab 0,3 mg.

A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Evaluating the long term safety and tolerability of ranibizumab treatment of AMD patients.

Follow up after Treated Circumscribed Choroidal Haemangioma with Photodynamic Therapy

Long-term follow up of patients treated with limited PDT, for a symptomatic circumscribed choroidal hamangioma, in search of possible late unwanted side effects of PDT treatment and recurrence of leakage.

E-mental health intervention for patients with exudative retinal diseases who receive intraocular anti-VEGF injections (E-PsEYE) - pilot study

To investigate if E-PsEYE leads to a reduction in depression and anxiety symptoms (primary outcomes) and problems with adaptation to vision loss(secondary outcome). Conducting a process evaluation to determine adherence and patient satisfaction. To…

Optical coherence tomography and widefield fundus photography for 3D radiation- dose response relationship in partial eye irradiation

To gain insight into the incidence of retinopathy and optic neuropathy in relation to the radiation dose in order to develop a normal tissue complication probability (NTCP) model for the eye and the optic tract.

A MULTICENTER, OPEN-LABEL EXTENSION
STUDY TO EVALUATE THE LONG-TERM SAFETY
AND TOLERABILITY OF FARICIMAB IN PATIENTS
WITH NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION

This study will evaluate the long-term safety and tolerability of IVT faricimab in patients with nAMD who have completed either of the Phase III (GR40306 or GR40844) studies. Additional assessments relating to efficacy, pharmacokinetics,…

An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090

This extension study aims to collect long-term data on safety and efficacy in a subject population treated for ROP with aflibercept and/or laser, and to contribute to the clarification of potential effects.

The Vitreous Wipe. Clinical evaluation of an investigational medical device.

To establish the proportion of complete vitreoschisis removal with PVA.